How Lobbying for Rare Disease Research Influences Congress and NIH – Pharmalot – WSJ

“For years, patient advocates and families have lobbied Congress for more funds to combat rare diseases. But to what extent does lobbying make a difference when Congress sets appropriations and the National Institutes of Health makes funding decisions?”

Read more – Pharmalot – WSJ